Compare Natera Inc. Common Stock (NTRA) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rockwell Automation — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Rockwell Automation trades at $419.58 (market cap $48.01B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Rockwell Automation pays a 1.28% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rockwell Automation for 74 Days on average.
| NTRA | ROK | |
|---|---|---|
Market Cap | $57.03B | $48.01B |
Volume | 1,131,157 | 919,883 |
Sector | Health | Industrials |
52-Week High | $425.64 | $495.08 |
52-Week Low | $179.42 | $347.66 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $56.18B | $51.14B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Rockwell Automation (ROK) trades at $423.42, down 2.43% amid bearish technical signals, though it maintains strong profitability with 34.47% ROE and has beaten earnings estimates for three consecutive quarters. The company shows robust cash flow generation of $1.54B from operations in 2025 and continues to lead in industrial automation with recent partnerships in AI cybersecurity and biotech automation.
While valuation multiples appear elevated with a P/E of 40.48, analyst consensus targets $489.89 offering 16% upside potential. Key risks include cyclical industrial demand and margin pressure, but the company's strategic positioning in digital transformation provides long-term growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
